Oral salmon calcitonin: Complete Phase III enrollment

Novartis and Nordic completed enrollment of more than 900 patients ages 51-80 in a 2-year, double-blind, placebo-controlled, international Phase III trial evaluating 0.8 mg of oral SMC021 given twice ...